Clinical Trial Update: A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating NCR102 for safety and efficacy in subjects with acute graft-versus-host disease; the study status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• NCR102

Snippet

Sponsor: Nuwacell Biotechnologies Co., Ltd. | Conditions: Acute Graft-versus-Host Disease | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING